Want to see ERAS full AI Analyst Report?
ERAS Stock Chart & Stats
$19.01
-$0.05(-2.00%)
At close: 4:00 PM EST
$19.01
-$0.05(-2.00%)
Day’s Range― - ―
52-Week Range$1.33 - $24.28
Previous CloseN/A
Volume148.24K
Average Volume (3M)5.78M
Market Cap
$6.65B
Enterprise Value$4.73K
Total Cash (Recent Filing)$243.79M
Total Debt (Recent Filing)$45.95M
Price to Earnings (P/E)―
Beta1.85
Next Earnings
Aug 06, 2026EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.93
Shares Outstanding347,127,400
10 Day Avg. Volume6,108,733
30 Day Avg. Volume5,780,192
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)3.24
Price to Sales (P/S)0.00
P/FCF Ratio-11.03
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$22.56Price Target Upside18.65% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-0.95
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Promising ERAS-0015 Phase 1 EfficacyRobust early monotherapy activity (high ORRs and durable on-treatment responses) indicates ERAS-0015 may be a best-in-class pan‑RAS asset. Clinically meaningful activity in hard-to-treat KRAS indications supports the case for registration‑enabling trials and durable commercial differentiation if confirmed.
Large Equity Raise To Fund DevelopmentA sizable primary equity offering materially strengthens the company’s cash runway, reducing near‑term financing risk and enabling acceleration of Phase 3/registration programs. Secured funding supports execution of multi‑year clinical plans and partnership or combo studies critical to long‑term program value.
Low Leverage And A Meaningful Equity BaseRelative balance sheet strength with low debt levels provides financial flexibility typical for a development biotech, limiting creditor constraints. A sizable equity base and manageable debt position improve capacity to absorb additional R&D funding needs and support strategic investments without immediate solvency pressure.
Bears Say
No Revenue And Large Net LossesThe company remains pre‑commercial with negligible revenue and substantial recurring net losses, meaning long‑term sustainability depends entirely on external financing or successful product approval. Persistent negative earnings weaken internal funding capacity and increase dilution or partnership dependency risks.
High And Accelerating Cash BurnOperating and free cash flows are deeply negative and have worsened recently, signalling accelerating cash consumption to support trials. Even with new capital, sustained high burn limits optionality, raises probability of further financings, and constrains ability to expand parallel development programs without dilution or partner deals.
Patent/legal Challenge To ERAS-0015A formal allegation of infringement and misappropriation against a core asset is a structural risk: it can delay U.S. development, lead to injunctions or royalties, increase costs, and complicate partnering or commercialization. Litigation outcomes could materially constrain long‑term value of the lead program.
Erasca News
ERAS FAQ
What was Erasca, Inc.’s price range in the past 12 months?
Erasca, Inc. lowest stock price was $1.33 and its highest was $24.28 in the past 12 months.
What is Erasca, Inc.’s market cap?
Erasca, Inc.’s market cap is $6.65B.
When is Erasca, Inc.’s upcoming earnings report date?
Erasca, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 17 days.
How were Erasca, Inc.’s earnings last quarter?
Erasca, Inc. released its earnings results on May 11, 2026. The company reported -$0.6 earnings per share for the quarter, missing the consensus estimate of -$0.104 by -$0.496.
Is Erasca, Inc. overvalued?
According to Wall Street analysts Erasca, Inc.’s price is currently Undervalued.
Does Erasca, Inc. pay dividends?
Erasca, Inc. does not currently pay dividends.
What is Erasca, Inc.’s EPS estimate?
Erasca, Inc.’s EPS estimate is -0.11.
How many shares outstanding does Erasca, Inc. have?
Erasca, Inc. has 347,127,400 shares outstanding.
What happened to Erasca, Inc.’s price movement after its last earnings report?
Erasca, Inc. reported an EPS of -$0.6 in its last earnings report, missing expectations of -$0.104. Following the earnings report the stock price went down -0.575%.
Which hedge fund is a major shareholder of Erasca, Inc.?
Currently, no hedge funds are holding shares in ERAS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Erasca Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$22.56 (18.65% Upside)
$22.56 (18.65% Upside)
Blogger Sentiment
Bullish
ERAS Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 965.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 11.6%
Last 30 Days ▲ 11.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
1186.57%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-2.12%
Trailing 12-Months
Company Description
Erasca, Inc.
Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.
ERAS Stock 12 Month Forecast
Average Price Target
$22.56
▲(18.65% Upside)
Technical Analysis
Arcturus Therapeutics
―
Arvinas Holding Company
―
―
Olema Pharmaceuticals
―
Bicara Therapeutics Inc.
―
Ownership Overview
9.72% Insiders
11.43% Mutual Funds
0.31% Other Institutional Investors
67.75% Public Companies and Individual Investors